PRELUDE THERAPEUTICS INC Restricted Cash
PRELUDE THERAPEUTICS INC (PRLD) had Restricted Cash of $3.40 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2026-08-11
- 2026-06-30: Restricted Cash $3.40M.
- 2026-03-31: Restricted Cash $3.23M.
- 2025-12-31: Restricted Cash $3.23M.
- 2025-09-30: Restricted Cash $3.23M.
| Period end | Restricted Cash |
|---|---|
| 2026-06-30 | $3.40M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $3.23M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $3.23M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $3.23M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $4.04M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $4.04M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $4.04M 10-K · filed 2026-03-10 |
| 2024-09-30 | $4.04M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $4.04M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $4.04M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $4.04M 10-K · filed 2025-03-10 |
| 2023-09-30 | $4.04M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $4.04M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $4.04M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $4.04M 10-K · filed 2024-02-15 |
| 2022-09-30 | $4.04M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $4.04M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $4.04M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $4.04M 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |